
Sign up to save your podcasts
Or


Axios Re:Cap is revisiting some of this year’s biggest stories and what they say about where technology, business, politics and more are headed in 2022.
Alison Snyder, managing editor and author of Axios Science, joins Axios Re:Cap senior producer Naomi Shavin to discuss a major research trend that flew under the radar this year: increased public and private funding for trials looking into therapeutic psychedelics.
By Axios4.3
689689 ratings
Axios Re:Cap is revisiting some of this year’s biggest stories and what they say about where technology, business, politics and more are headed in 2022.
Alison Snyder, managing editor and author of Axios Science, joins Axios Re:Cap senior producer Naomi Shavin to discuss a major research trend that flew under the radar this year: increased public and private funding for trials looking into therapeutic psychedelics.

32,263 Listeners

30,678 Listeners

8,788 Listeners

26,397 Listeners

112,982 Listeners

56,868 Listeners

10,330 Listeners

5,449 Listeners

6,119 Listeners

564 Listeners

5,671 Listeners

10,231 Listeners

6,446 Listeners

2,020 Listeners

5,544 Listeners

4,364 Listeners

16,366 Listeners